Death in the Line of Duty... Fire Fighter Fatality Investigation and Prevention Program

Total Page:16

File Type:pdf, Size:1020Kb

Death in the Line of Duty... Fire Fighter Fatality Investigation and Prevention Program 2010 08 Death in the line of duty... Fire Fighter Fatality Investigation and Prevention Program A summary of a NIOSH fire fighter fatality investigation June, 2010 Major Suffers Sudden Cardiac Death During Physical Fitness Training – Kentucky Executive Summary Introduction & Methods On January 17, 2010, a 51-year-old male volunteer On January 17, 2010, a 51-year-old male volun- Major responded to a reported residential fire. The teer Major died after performing physical fitness reported fire turned out to be steam from a shower. training. NIOSH was notified of this fatality on Three hours after returning home, the Major went January 19, 2010, by the U.S. Fire Administration. to exercise at a local fitness facility with his trainer. NIOSH contacted the affected FD on February After walking on a treadmill for approximately 25 5, 2010, to gather additional information, and on minutes, the Major had a short cool down period March 17, 2010, to initiate the investigation. On when he suddenly collapsed. Cardiopulmonary March 25, 2010, a safety and occupational health resuscitation (CPR) and advanced life support were specialist from the NIOSH Fire Fighter Fatality begun as an ambulance was requested. Despite CPR Investigation Team traveled to Kentucky to con- and advanced life support by the fitness center staff, duct an on-site investigation of the incident. fire department (FD) emergency medical technicians, ambulance paramedics, and hospital’s emergency During the investigation, NIOSH personnel inter- department (ED) staff, the Major died. The death viewed the following people: certificate, completed by the attending physician, • Fire Chief listed “ischemic heart disease with cardiac arrest” • Fire Marshal due to “coronary artery disease” as the cause of death. • Safety Officer The autopsy, completed by the County Coroner, • Crewmembers listed “ischemic heart disease” as the cause of death. • Fitness center Director Given the Major’s severe underlying coronary artery disease (CAD), NIOSH investigators concluded that NIOSH personnel reviewed the following docu- the physical exertion involved in performing physical ments: fitness training triggered his sudden cardiac death. • FD training records • FD annual report for 2009 NIOSH investigators offer the following • FD incident report recommendations to address general safety and health • FD medical records issues. It is unclear if these recommendations would • Emergency medical service (ambulance) inci- have prevented the Major’s death. dent report • Hospital ED records Perform an annual physical performance (physical • Death certificate ability) evaluation. • Autopsy report • Primary care provider medical records Phase in a comprehensive wellness and fitness • Fitness center report program for fire fighters. A Summary of a NIOSH fire fighter fatality investigation Report #2010-08 Major Suffers Sudden Cardiac Death During Physical Fitness Training – Kentucky The National Institute for Occupational Safety and Health (NIOSH) initiated the Fire Fighter Fatality Investigation and Prevention Program to examine deaths of fire fighters in the line of duty so that fire departments, fire fighters, fire service organizations, safety experts and researchers could learn from these incidents. The primary goal of these investigations is for NIOSH to make recommendations to prevent similar occurrences. These NIOSH investigations are intended to reduce or prevent future fire fighter deaths and are completely separate from the rulemaking, enforcement and inspection activities of any other federal or state agency. Under its program, NIOSH investigators interview persons with knowledge of the incident and review available records to develop a description of the conditions and circumstances leading to the deaths in order to provide a context for the agency’s recommendations. The NIOSH summary of these conditions and circumstances in its reports is not intended as a legal statement of facts. This summary, as well as the conclusions and recommendations made by NIOSH, should not be used for the purpose of litigation or the adjudication of any claim. For further information, visit the program website at www.cdc.gov/niosh/fire or call toll free 1-800-CDC-INFO (1-800-232-4636). Page 2 A Summary of a NIOSH fire fighter fatality investigation Report #2010-08 Major Suffers Sudden Cardiac Death During Physical Fitness Training – Kentucky Investigative Results Incident. On January 17, 2010, the FD was dis- AED to the Major, which advised a shock (defi- patched to a residential structure fire at 1330 brillation). One shock was delivered. hours. The Major, on call for the weekend, re- sponded from his home to the scene. Units arrived The advanced life support ambulance staffed with on the scene at 1337 hours and determined the paramedics arrived on the scene at 1749 hours. “smoke” was actually steam from a shower. Units The AED advised to shock again, and a second were released from the scene at 1340 hours. shock was delivered. CPR continued; the Major was placed into the ambulance where he was intu- The Major went home for approximately 3 hours. bated. Tube placement was confirmed by end tidal At approximately 1700 hours, he went to a local CO2 detector [AHA 2005]. Intravenous access fitness facility to exercise. He had joined the facil- was attained and cardiac resuscitation medications ity at the beginning of January and a trainer was were administered as the ambulance departed the assigned to assist him with his fitness program. scene at 1758 hours en route to the hospital’s ED. After speaking with the trainer, the Major walked Advanced life support continued during the 9 min- on the treadmill for 5 minutes to warm up and ute trip to the hospital. have his heart rate checked; his heart rate was 100 beats per minute. The trainer then showed the Ma- The ambulance arrived at the ED at 1807 hours. jor various aspects of the treadmill and the Major Inside the ED, advanced life support continued walked for an additional 20 minutes. The Major’s without change in the Major’s condition until heart rate was checked three times and remained 1817 hours, when the attending physician pro- around 100 beats per minute. After cooling down, nounced the Major dead and resuscitation efforts the Major walked to the hallway, drank some were discontinued. water, and returned to the exercise room and the trainer. As the trainer turned to speak to someone, Medical Findings. The death certificate, completed the Major collapsed. by the attending physician, listed “ischemic heart disease with cardiac arrest” due to “coronary ar- 911 was called and an advanced life support tery disease” as the cause of death. The autopsy, ambulance and the FD were dispatched at 1740 completed by the County Coroner, listed “ischemic hours. Fitness center staff retrieved an automated heart disease” as the cause of death. Specific find- external defibrillator (AED) as CPR was begun. ings from the autopsy are listed in Appendix A. Two off-duty nurses were exercising at the facility and came to render aid. As the fitness center staff The Major was 74 inches tall and weighed 253 attempted to apply the AED, a nurse said she felt a pounds, giving him a body mass index (BMI) of pulse; the AED was not used. 32.5 kilograms per meters squared (kg/m2). A BMI > 30.0 kilograms per meter squared is con- The FD engine arrived on the scene at 1744 hours. sidered obese [CDC 2010]. The Major’s risk fac- Fire fighter/EMTs found the Major unresponsive, tors for coronary artery disease (CAD) included not breathing, with no pulse, and CPR in progress. hypercholesterolemia (high blood cholesterol) and EMTs inserted a nasal airway and attached the obesity/lack of exercise. He had not been pre- Page 3 A Summary of a NIOSH fire fighter fatality investigation Report #2010-08 Major Suffers Sudden Cardiac Death During Physical Fitness Training – Kentucky Investigative Results (cont.) Description of the Fire Department scribed any lipid-lowering medications and had At the time of the NIOSH investigation, the com- begun a self-initiated exercise program in January bination FD consisted of one fire station with 54 2010. uniformed personnel that served 28,000 residents in a geographic area of 7.3 square miles. In 2009, In 2001, the Major was evaluated for acute chest the FD responded to 791 calls including 287 struc- discomfort. An echocardiogram revealed right ture fires, 16 field fires, 11 trash fires, 10 vehicle ventricular hypertrophy (thickened right ven- fires, 2 dumpster fires, 82 hazardous condition tricle). He performed an exercise stress test at calls, 18 hazardous material calls, 24 false calls, which he exercised for 11 minutes, 15 seconds on 30 assist calls, 157 other calls, and 154 first re- the Bruce protocol and stopped due to shortness of sponder calls. breath and fatigue. The test was deemed negative for ischemia and infarction, and the Major was Employment, Membership, and Training. The cleared for duty. FD requires new career fire fighter applicants to be State-certified to the 150-hour level, complete At a FD medical evaluation in 2001, the Major an application, be 18 years of age (21 years old to was diagnosed with mild sleep apnea but this was drive fire apparatus), have a valid State driver’s li- not considered serious enough to restrict his duties cense, pass a written examination, pass a physical as a fire fighter. However, in 2007 his primary care ability test, and pass an interview prior to being physician referred the Major to a sleep clinic. At hired. The new hire must then pass a drug screen, a FD medical evaluation in 2008, the physician a preplacement medical evaluation (including required the Major to get a clearance from his exercise stress test), and a self-contained breathing primary care physician regarding his sleep apnea; apparatus mask fit test. The new hire is placed on specifically, that the condition had been treated a shift where the hours of duty are 24 hours on- adequately for over 30 days.
Recommended publications
  • The Meaning of Different Forms of Structural Myocardial Injury, Immune Response and Timing of Infarct Necrosis and Cardiac Repair
    CORE Metadata, citation and similar papers at core.ac.uk Provided by Archivio della ricerca- Università di Roma La Sapienza Send Orders for Reprints to [email protected] 6 Current Vascular Pharmacology, 2015, 13, 6-19 The Meaning of Different Forms of Structural Myocardial Injury, Immune Response and Timing of Infarct Necrosis and Cardiac Repair Emanuela Turillazzi1*, Cristoforo Pomara1, Stefania Bello1, Margherita Neri1, Irene Riezzo1 and Vittorio Fineschi2 1Institute of Legal Medicine, Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy; 2Department of Anatomical, Histological, Forensic and Orthopaedic Sciences, Sapienza Uni- versity of Rome, Rome, Italy Abstract: Although a decline in the all-cause and cardiac mortality rates following myocardial infarction (MI) during the past 3 decades has been reported, MI is a major cause of death and disability worldwide. From a pathological point of view MI consists in a particular myocardial cell death due to prolonged ischemia. After the onset of myocardial ischemia, cell death is not immediate, but takes a finite period of time to develop. Once complete myocytes’ necrosis has occurred, a process leading to a healed infarction takes place. In fact, MI is a dynamic proc- ess that begins with the transition from reversible to irreversible ischemic injury and culminates in the replacement of dead myocardium by a fibrous scar. The pathobiological mechanisms underlying this process are very complex, involving an in- flammatory response by several pathways, and pose a major challenge to ability to improve our knowledge. An improved un- derstanding of the pathobiology of cardiac repair after MI and further studies of its underlying mechanisms provide avenues for the development of future strategies directed toward the identification of novel therapies.
    [Show full text]
  • Management of Chronic Problems
    MANAGEMENT OF CHRONIC PROBLEMS ALCOHOLIC MYOPATHY A. Chaudhuri* P.O. Behan† INTRODUCTION muscles. The clinical picture may be confused with venous Alcohol has been an integral part of man’s social history thrombophlebitis when muscle involvement is asymmetric5 since antiquity. After the art of distillation was rediscovered and, rarely, dysphagia can also occur. ARM may be associated in the Middle Ages, alchemists found, in ethanol, a cure for with signs of acute liver injury (acute alcoholic hepatitis) every illness, a tradition that still continues in this age with and congestive cardiac failure. Electromyography (EMG) the Gaelic name for whisky (usquebaugh, meaning ‘water of shows profuse fibrillations and myopathic changes similar life’). In more recent times researchers have wondered to acute polymyositis. Attacks of ARM may recur on a why the enzyme alcohol dehydrogenase, which converts number of occasions following alcoholic binges. ethanol to its major metabolite, acetaldehyde, exists in the Following its original description by Hed et al. in 1962,5 body if alcohol has no physiological role. acute alcoholic myopathy is now known to present with Though ‘alcohol’ is a generic name, in practice it usually variable severity, ranging from transient asymptomatic rises means ‘ethyl alcohol’ or ‘ethanol’ (C2H5OH). Other aliphatic in serum CK and myoglobin levels to a more fulminant alcohols include methyl alcohol (methanol) and isopropyl rhabdomyolysis, myoglobinuria and renal failure.6,7 It has alcohol, both of which are used as industrial solvents, are been recently suggested that magnetic resonance (MR) occasionally implicated in accidental human poisoning and imaging of thigh and leg muscles may be useful in the have no reported direct effect on skeletal muscles.
    [Show full text]
  • Toxicological Profile for Hydrazines. US Department Of
    TOXICOLOGICAL PROFILE FOR HYDRAZINES U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Agency for Toxic Substances and Disease Registry September 1997 HYDRAZINES ii DISCLAIMER The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry. HYDRAZINES iii UPDATE STATEMENT Toxicological profiles are revised and republished as necessary, but no less than once every three years. For information regarding the update status of previously released profiles, contact ATSDR at: Agency for Toxic Substances and Disease Registry Division of Toxicology/Toxicology Information Branch 1600 Clifton Road NE, E-29 Atlanta, Georgia 30333 HYDRAZINES vii CONTRIBUTORS CHEMICAL MANAGER(S)/AUTHOR(S): Gangadhar Choudhary, Ph.D. ATSDR, Division of Toxicology, Atlanta, GA Hugh IIansen, Ph.D. ATSDR, Division of Toxicology, Atlanta, GA Steve Donkin, Ph.D. Sciences International, Inc., Alexandria, VA Mr. Christopher Kirman Life Systems, Inc., Cleveland, OH THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS: 1 . Green Border Review. Green Border review assures the consistency with ATSDR policy. 2 . Health Effects Review. The Health Effects Review Committee examines the health effects chapter of each profile for consistency and accuracy in interpreting health effects and classifying end points. 3. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to substance-specific minimal risk levels (MRLs), reviews the health effects database of each profile, and makes recommendations for derivation of MRLs. HYDRAZINES ix PEER REVIEW A peer review panel was assembled for hydrazines. The panel consisted of the following members: 1. Dr.
    [Show full text]
  • January 22, 2013
    January 22, 2013 Dear Centers for Medicare & Medicaid Services, I am writing to make a formal request for a new national coverage determination (NCD) for the AlloMap gene expression test that is provided by XDx Expression Diagnostics. I am formally requesting that Medicare choose not to pay a reimbursement for this test, which is an inferior diagnostic test. I will make this case using the publically available evidence below. The AlloMap gene test falls under the benefit category: diagnostic test. The AlloMap gene expression test is designed to identify individuals in need of a heart biopsy to identify acute cellular rejection in a heart transplant population. As such, this test is useful in only a small percentage of Medicare patients. It was approved by the FDA (510(k) Number: k073482) in 2008. From the FDA file k073482, the indications for use are as follows: Indication(s) for use: AlloMap Molecular Expression Testing is an In Vitro Diagnostic Multivariate Index assay (IVDMIA) test service, performed in a single laboratory, assessing the gene expression profile of RNA isolated from peripheral blood mononuclear cells (PBMC). AlloMap Testing is intended to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection (ACR) at the time of testing in conjunction with standard clinical assessment. Indicated for use in heart transplant recipients: • 15 years of age or older • At least 2 months (≥55 days) post-transplant Traditionally, the surveillance of heart transplant recipients for acute cellular rejection (ACR) and antibody mediated rejection (humoral, AMR) has been performed through the interactions of cardiologists and pathologists.
    [Show full text]
  • Consensus Statement on Endomyocardial Biopsy
    Cardiovascular Pathology 21 (2012) 245–274 Original Article 2011 Consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology ⁎ ⁎ Ornella Leone a, , John P. Veinot b, , Annalisa Angelini c, Ulrik T. Baandrup d, Cristina Basso c, Gerald Berry e, Patrick Bruneval f, Margaret Burke g, Jagdish Butany h, Fiorella Calabrese c, Giulia d'Amati i, William D. Edwards j, John T. Fallon k, Michael C. Fishbein l, Patrick J. Gallagher m, Marc K. Halushka n, Bruce McManus o, Angela Pucci p, E. René Rodriguez q, Jeffrey E. Saffitz r, Mary N. Sheppard g, Charles Steenbergen n, James R. Stone r, Carmela Tan q, Gaetano Thiene c, Allard C. van der Wal s, Gayle L. Winters r aBologna, Italy bOttawa, Ontario, Canada cPadua, Italy dHjoerring, Denmark eStanford, CA, USA fParis, France gLondon, UK hToronto, Ontario, Canada iRome, Italy jRochester, MN, USA kNew York, NY, USA lLos Angeles, CA, USA mSouthampton, UK nBaltimore, MD, USA oVancouver, BC, Canada pPisa, Italy qCleveland, OH, USA rBoston, MA, USA sAmsterdam, The Netherlands Received 3 August 2011; received in revised form 28 September 2011; accepted 7 October 2011 Abstract The Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology have produced this position paper concerning the current role of endomyocardial biopsy (EMB) for the diagnosis of cardiac diseases and its contribution to patient management, focusing on pathological issues, with these aims: • Determining appropriate EMB use in the context of current diagnostic strategies for cardiac diseases and providing recommendations for its rational utilization ⁎ Corresponding authors. O. Leone is to be contacted at U.O.
    [Show full text]
  • Cardiac Damage After Ischemic Stroke in Diabetic State
    REVIEW published: 27 August 2021 doi: 10.3389/fimmu.2021.737170 Cerebral-Cardiac Syndrome and Diabetes: Cardiac Damage After Ischemic Stroke in Diabetic State † † Hong-Bin Lin 1 , Feng-Xian Li 1 , Jin-Yu Zhang 2, Zhi-Jian You 3, Shi-Yuan Xu 1, Wen-Bin Liang 4* and Hong-Fei Zhang 1* Edited by: 1 Department of Anesthesiology, Zhujiang Hospital of Southern Medical University, Guangzhou, China, 2 State Key Laboratory of Junlei Chang, Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China, 3 Guangxi Health Commission Key Shenzhen Institutes of Advanced Laboratory of Clinical Biotechnology, Liuzhou People’s Hospital, Liuzhou, China, 4 University of Ottawa Heart Institute and Technology, Chinese Academy of Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON, Canada Sciences (CAS), China Reviewed by: Xinchun Jin, Cerebral-cardiac syndrome (CCS) refers to cardiac dysfunction following varying brain Capital Medical University, China injuries. Ischemic stroke is strongly evidenced to induce CCS characterizing as Xia Li, arrhythmia, myocardial damage, and heart failure. CCS is attributed to be the second Fourth Military Medical University, China leading cause of death in the post-stroke stage; however, the responsible mechanisms *Correspondence: are obscure. Studies indicated the possible mechanisms including insular cortex injury, Wen-Bin Liang autonomic imbalance, catecholamine surge, immune response, and systemic [email protected] fl Hong-Fei Zhang in ammation. Of note, the characteristics of the stroke population reveal a common [email protected] comorbidity with diabetes. The close and causative correlation of diabetes and stroke †These authors have contributed directs the involvement of diabetes in CCS.
    [Show full text]
  • Small Cardiac Lesions Fibrosis of Papillary Muscles and Focal
    Small Cardiac Lesions Fibrosis of Papillary Muscles and Focal Cardiac Myocytolysis Arthur STEER, M.D.,1 Teruyuki NAKASHIMA, M.D.,2 Taketsugu KAWASHIMA, M.D.,1 Kelvin K. LEE, M.A.,3 Michael D. DANZIG, M.D.,4* Thomas L. ROBERTSON M.D.,4** and Donald S. DOCK, M.D.4 SUMMARY Three types of small cardiac lesions were described and illustrated: (1) focal type of papillary muscle fibrosis, evidently a healed infarct of the papillary muscle present in 13% of the autopsies, is a histologically characteristic lesion associated with coronary artery disease and healed myocardial infarction, (2) diffuse type of papillary muscle fibrosis, prob- ably an aging change present in almost half of the autopsies, is associated with sclerosis of the arteries in the papillary muscle, is identifiable his- tologically, and apparently is not associated with any cardiac abnormal- ity, and (3) focal cardiac myocytolysis, a unique histologic lesion, usually multifocal without predilection for any area of the heart, is associated with ischemic heart disease, death due to cancer complicated by non- bacterial thrombotic endocarditis and microthrombi in small cardiac arteries as well as with other diseases. Differentiation of the 2 types of papillary muscle fibrosis is important in the study of papillary muscle and mitral valve dysfunction. Focal cardiac myocytolysis may contribute to the fatal extension of myocardial infarcts. From the Radiation Effects Research Foundation Hiroshima and Nagasaki. A Cooperative Research Institute supported by funds from the U.S.A. National Academy of Sciences-National Research Council, Atomic Energy Commission and Environmental Protection Agency and from the Japanese National Institute of Health of the Ministry of Health and Welfare.
    [Show full text]
  • Inflammatory Heart Diseases –
    Cardiovascular Pathology – inflammatory heart diseases – Semmelweis University 2017/2018 – Autumn Semester 2nd Department of Pathology Tibor Glasz MD PhD _______ _______ _______ _______ Inflammatory cardiac diseases ____________________ _____________________ Inflammatory heart diseases - Endocarditides - parietal - valvular - Myocarditis Pancarditis - Pericarditis Endocarditides The infective endocarditides - Risk groupes: ~ rheumatic or degenerative valvular deformities ~ congenital valvular vitia ~ valvular prostheses ~ arterial long-term catheter ~ intravenous drug abusers (15% of cases, here: localisation typically tricuspidal!) - Infective agents: ~ almost always bacteria (Staphylococcus auerus, Streptococcus viridans, Gonococci, Enterobacteria; in immunodeficiency: so-called opportunistic bacteria) ~ seldom fungi (in immunodeficiency /AIDS/ and iv. drug abusers) http://images.md Congenital bicuspidy The infective endocarditides - Clinical forms: ~ acute: sudden beginning with high fever and septic crisis > despite antibiotics mortality very high ~ subacute (endocarditis subacuta infectiva/lenta): begins inconspicuously with uncharacteristic systemic symptoms (weakness, fever, weight loss) The infective endocarditides - Morphology: the same in both forms: ~ valvular vegetations along the closing lines of the valves: from small, finely granular to gross polypoid, stenosing ~ the material of the vegetations may harbour large amounts of infective agents and is highly friable > danger of embolism > formation of metastatic abscesses
    [Show full text]
  • General Characteristics of Cardiac Infarct Cardiac Infarct Comprises Three Phases: Necrosis, Reactive Exuda- Tion, and Repair
    FOCAL MYOCYTOLYSIS OF THE HEART * MONROE J. SCHLESINGER, M.D.,t and LEOPOLD REmIm, M.D. From the Pathology Laboratory, Beth Israel Hospital, and the Department of Pathology, Harvard Medical School, Boston, Mass. In this communication we wish to focus attention on a miliary lesion of the myocardium not hitherto emphasized and commonly seen in coronary heart disease. We have characterized the lesion as focal myocytolysis. Others have described it under various designations such as acute miliary infarction,l focal necrotizing myocarditis with- out interstitial infiltration,2 and sarcolytic myocardosis.3 Focal myocytolysis as it appears at the borders of cardiac infarcts was appreciated as early as I904 by Smith,4 but seemingly has since been forgotten. It has been described also in various non- coronary cardiac conditions.' 2'5-9 Focal myocytolysis of the heart has been noted in several diseases not essentially cardiac.3 12 It has been produced experimentally in a variety of animals.1318 In spite of its rather common occurrence, its morphologic and functional significance has not been appreciated generally. In speed of evolution and histologic details, focal myocytolysis is intermediate between the reversible degenerations of the myocardium and the irreversible coagulation necrosis of an infarct. The lesion is closely similar to, and probably has been confused with, some forms of infarction. Hence, it is necessary first to delineate our concept of infarction in the heart. General Characteristics of Cardiac Infarct Cardiac infarct comprises three phases: necrosis, reactive exuda- tion, and repair. By standard morphologic criteria, an infarct does not become demonstrable, grossly or histologically, for I2 to 24 hours after its clinical onset.
    [Show full text]
  • Conducting Tissue of the Heart in Kwashiorkor
    Br Heart J: first published as 10.1136/hrt.34.8.828 on 1 August 1972. Downloaded from British Heart J'ournal, I972, 34, 828-829. Conducting tissue of the heart in kwashiorkor B. A. Sims From the Department of Pathology, Queen's University of Belfast The conducting tissue of the heart was examined histologically in 7 cases of kwashiorkor. Atro- phic changes were found, and in 5 cases myocytolysis was present. No cellular reaction orfibrous repair was found in relation to the areas of myocytolysis. These findings may be associated with a disturbance of atrioventricular conduction during life, perhaps accounting for some of the unexplained sudden deaths occurring in children with kwashiorkor. There is now considerable evidence to suggest The children in the 7 cases were aged i to 3 that the heart is involved in kwashiorkor. years, showing skin changes and oedema Gopalan (I955) reported electrocardiographic characteristic of kwashiorkor in most in- abnormalities such as bradycardia, T wave stances. The commonest cause of death was changes, and a prolonged QT interval, while a respiratory infection. histologically there was atrophy of the cardiac Histological examination of the myocar- muscle fibres. A special study of the heart in dium shows the muscle fibres to be atrophic kwashiorkor was made by Smythe, Swane- but no degenerative change is evident. In the poel, and Campbell (I962) in which they conducting tissue the wasting of the fibres is analysed the electrocardiogram to find T wave more obvious. They contain vacuoles and are inversion and a prolonged QT interval. surrounded by interstitial oedema as shown Histological examination in 24 cases revealed in the Fig.
    [Show full text]
  • Dilated Cardiomyopathy
    PRIMER Dilated cardiomyopathy Heinz- Peter Schultheiss1,2*, DeLisa Fairweather3*, Alida L. P. Caforio4, Felicitas Escher1,2,5, Ray E. Hershberger6, Steven E. Lipshultz7,8,9, Peter P. Liu10, Akira Matsumori11, Andrea Mazzanti12,13, John McMurray14 and Silvia G. Priori12,13 Abstract | Dilated cardiomyopathy (DCM) is a clinical diagnosis characterized by left ventricular or biventricular dilation and impaired contraction that is not explained by abnormal loading conditions (for example, hypertension and valvular heart disease) or coronary artery disease. Mutations in several genes can cause DCM, including genes encoding structural components of the sarcomere and desmosome. Nongenetic forms of DCM can result from different aetiologies, including inflammation of the myocardium due to an infection (mostly viral); exposure to drugs, toxins or allergens; and systemic endocrine or autoimmune diseases. The heterogeneous aetiology and clinical presentation of DCM make a correct and timely diagnosis challenging. Echocardiography and other imaging techniques are required to assess ventricular dysfunction and adverse myocardial remodelling, and immunological and histological analyses of an endomyocardial biopsy sample are indicated when inflammation or infection is suspected. As DCM eventually leads to impaired contractility, standard approaches to prevent or treat heart failure are the first-line treatment for patients with DCM. Cardiac resynchronization therapy and implantable cardioverter–defibrillators may be required to prevent life-threatening
    [Show full text]
  • Bone Marrow Cell Migration to the Heart in a Chimeric Mouse Model of Acute Chagasic Disease
    Mem Inst Oswaldo Cruz, Rio de Janeiro, Vol. 112(8): 551-560, August 2017 551 Bone marrow cell migration to the heart in a chimeric mouse model of acute chagasic disease Camila Iansen Irion, Bruno Diaz Paredes, Guilherme Visconde Brasil, Sandro Torrentes da Cunha, Luis Felipe Paula, Alysson Roncally Carvalho, Antonio Carlos Campos de Carvalho, Adriana Bastos Carvalho, Regina Coeli dos Santos Goldenberg/+ Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brasil BACKGROUND Chagas disease is a public health problem caused by infection with the protozoan Trypanosoma cruzi. There is currently no effective therapy for Chagas disease. Although there is some evidence for the beneficial effect of bone marrow-derived cells in chagasic disease, the mechanisms underlying their effects in the heart are unknown. Reports have suggested that bone marrow cells are recruited to the chagasic heart; however, studies using chimeric mouse models of chagasic cardiomyopathy are rare. OBJECTIVES The aim of this study was to investigate the migration of bone marrow cells to the heart after T. cruzi infection in a model of chagasic disease in chimeric mice. METHODS To obtain chimerical mice, wild-type (WT) C57BL6 mice were exposed to full body irradiation (7 Gy), causing bone marrow ablation. Then, bone marrow cells from green fluorescent protein (GFP)-transgenic mice were infused into the mice. Graft effectiveness was confirmed by flow cytometry. Experimental mice were divided into four groups: (i) infected chimeric (iChim) mice; (ii) infected WT (iWT) mice, both of which received 3 × 104 trypomastigotes of the Brazil strain; (iii) non-infected chimeric (Chim) mice; and (iv) non-infected WT mice.
    [Show full text]